A venture capital firm with offices in Western Europe manages multiple life sciences investment funds focused on therapeutics, diagnostics, and medical devices. The firm specializes in early-stage healthcare investments and typically commits approximately €5–12M per portfolio company over multiple financing rounds. The firm primarily invests in European companies and is recognized for its hands-on investment approach and close collaboration with leading academic and clinical research institutions.
The firm invests across therapeutics, diagnostics, and medical devices, with a primary focus on therapeutics. The firm is modality- and indication-agnostic, evaluating innovative technologies that are approximately 12 months or less from entering the clinic, as well as programs in Phase I and Phase II clinical development. In addition to traditional venture investing, the firm operates as a company builder, collaborating with academic institutions and industrial partners to identify promising scientific discoveries and establish new biotechnology companies.
From a company and management team perspective, the firm seeks companies with differentiated science and clear value-creation pathways that can achieve strategic exit opportunities within approximately three to five years, often through partnerships or acquisitions by pharmaceutical companies. The firm works closely with founders, academic innovators, and industry partners to accelerate company formation, development, and commercialization.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment